Hong Kong IVD Registration

IVD registration in Hong Kong, also known as “Listing”, is voluntary under the Medical Device Administrative Control System (MDACS).

Managed by the Medical Device Division (MDD) of the Department of Health, MDACS facilitates pre-market control of medical devices, including IVDs.

Though voluntary, IVD listing is strongly encouraged for procurement purposes by public hospitals, clinics, and the Hospital Authority.

Hong Kong IVD Registration
Voluntary registration in the Hong Kong market

How to List an IVD in Hong Kong

To list an IVD under MDACS, the manufacturer (foreign or local) must appoint a Local Responsible Person (LRP) and submit a registration application to the MDD with:

Scientific and medical writing including Clinical Evaluation Reports (CERs) and Performance Evaluation Reports (PERs)
Essential Principles Conformity Checklist for IVDs
Risk analysis and performance evaluation data
Instructions for use (IFU), labeling, and specimen collection details
Quality management system (QMS) certificate (e.g., ISO 13485)

IVD Conformity Assessment Requirements

The IVD must conform to the Technical Reference TR-004, which outlines the Essential Principles of Safety and Performance specific to IVDs. Depending on the classification, the MDD may request clinical performance data and additional documentation during review. The Hong Kong MDD evaluates whether the product meets these standards.

IVD Risk Classification in Hong Kong

Under the MDACS, Hong Kong applies the IMDRF IVD classification system, dividing IVDs into Classes A, B, C, and D based on risk. Only Classes B, C, and D are eligible for listing under the MDACS, similar to the classification of general medical devices in Classes II, III and IV.

The level of regulatory control increases as the risk classification of the devices rises, aligning with international guidelines to ensure compliance during the device registration process.

Class A: Lowest risk – not eligible for listing
Class B-D: Medium to high risk – eligible for voluntary listing.

Why List Your IVD Device in Hong Kong?

Since 1 November 2024, all Department of Health tenders require an MDACS Listing Number or Application Number for IVD devices.
MDACS listing increases credibility and access to public procurement, including Hospital Authority and public clinics.
A listed IVD device gains competitive advantage and is preferred in tenders over unlisted alternatives.
Registration supports Greater Bay Area (GBA) access and may support participation in the GBA Connect Scheme for urgently needed diagnostics in designated hospitals in Guangdong Province, including Shenzhen and Zhuhai.

China Greater Bay Area Connect Scheme for IVDs

The GBA Connect Scheme allows IVD devices without prior approval in China but with reference-country listings to be used in designated GBA hospitals. As of April 2026, 71 drugs and 91 medical devices have been approved via the scheme for importation to 71 GBA-designated hospitals. Hong Kong listing is a key stepping stone for manufacturers targeting the GBA and mainland China markets.

Our Hong Kong IVD Listing Services

We offer end-to-end support for IVD registration or listing in Hong Kong:

IVD risk classification and listing strategy
Guidance on best regulatory pathways
Labeling and UDI compliance support
Handling of Supplementary Notices, renewals, and post-listing changes.
Preparation and submission of:
  • Hong Kong MDACS Listing
  • Pre-filing applications for GBA approval
  • Expedited approval routes where eligible

Request a Proposal to List Your IVDs in Hong Kong

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

How Does GBA Real World Data Support China NMPA Approvals?

Discover how leveraging Real World Data generated in the Greater Bay Area can accelerate market entry for medical products in China.

October 12, 2026
How Does GBA Real World Data Support China NMPA Approvals?

FAQ: China Medical Device & IVD Registration

Get answers to common China medical device and IVD registration questions, from NMPA classification rules to testing and renewal requirements.

September 28, 2026
FAQ: China Medical Device & IVD Registration

When Is a Clinical Trial Required for China NMPA Medical Device Registration?

Find out when a clinical trial is required in China and when clinical evaluation, exemptions, overseas data, or other evidence may be sufficient.

September 17, 2026
When Is a Clinical Trial Required for China NMPA Medical Device Registration?
Detailed Description (for accessibility) A professional stock photo featuring an East Asian male doctor in his late 30s or early 40s wearing a crisp white lab coat over dark blue scrubs, with a stethoscope draped around his neck.

Is a Foreign Halal Certificate Valid in Indonesia? Requirements Explained

Understand Indonesia’s foreign halal certificate requirements, including covered categories and BPJPH registration routes.

September 4, 2026
Is a Foreign Halal Certificate Valid in Indonesia? Requirements Explained

Understanding Local Testing for Medical Devices & IVDs in Indonesia: Requirements & Registration Guide

Learn when local testing is required for medical devices and IVDs in Indonesia, which products are affected, and how testing impacts registration requirements.

August 31, 2026
Understanding Local Testing for Medical Devices & IVDs in Indonesia: Requirements & Registration Guide
An Indonesian male medical professional in profile, wearing dark blue scrubs, a blue surgical cap, safety glasses, a white mask, and a blue-tubed stethoscope, presses a button on a dual-monitor medical control panel in a clinical operating setting.

How China IVD Risk Classification Determines Your NMPA Registration Pathway

Learn how China IVD risk classification works under NMPA rules and see common compliance pitfalls to avoid.

July 13, 2026
How China IVD Risk Classification Determines Your NMPA Registration Pathway
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and outsourcing solutions to help your business thrive.

Hong Kong Local 
Responsible Person

We are your authorized representative in Hong Kong, and fulfill your listings as well as ensuring compliance with PMS requirements.

Learn more

Hong Kong Medical Device Listing

We’re with you every step of the way in getting your medical device listed in Hong Kong. From risk classification to navigating all regulatory requirements, we streamline the process to save you time and hassle.

Learn more

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

Drug Device Combination Products

We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Read the Latest Regulatory News

View More

Hong Kong Requires MDACS Listing for Injectable Dermal Fillers by March 1, 2027

New requirements could affect how injectable devices, including dermal fillers, are supplied in Hong Kong’s private healthcare sector.

September 29, 2026
Hong Kong Requires MDACS Listing for Injectable Dermal Fillers by March 1, 2027

TFDA Updates Processing Time Limits for Public Applications in Taiwan

Taiwan's TFDA has revised its processing time limits table for public applications, adding eight application items and amending two existing items.

September 9, 2026
TFDA Updates Processing Time Limits for Public Applications in Taiwan

Guangdong MPA Implements 2026 Guideline for Importing Hong Kong and Macao Drugs into the Greater Bay Area

The guideline introduces more detailed evidence requirements for Hong Kong and Macao drug imports while retaining a streamlined pathway for products already approved under the GBA Connect scheme.

August 31, 2026
Guangdong MPA Implements 2026 Guideline for Importing Hong Kong and Macao Drugs into the Greater Bay Area

Guangdong Releases 2026 Guideline for Importing Hong Kong and Macao Medical Devices into the Greater Bay Area

The revised 2026 GBA Connect Scheme framework sets higher bars for clinical need while fast-tracking repeat approvals for imported medical devices.

August 26, 2026
Guangdong Releases 2026 Guideline for Importing Hong Kong and Macao Medical Devices into the Greater Bay Area
Physician operates CT machine for a patient.

Hong Kong Introduces Measures for Priority Approval of Innovative Medical Devices

Updated MDACS guidance creates a new pathway for qualifying technologies and outlines the evidence required for priority consideration.

July 29, 2026
Hong Kong Introduces Measures for Priority Approval of Innovative Medical Devices

China CMDE Releases New Review Documents for Oncology NGS & HLA-B*58:01 Reagents

The new documents clarify expectations for Tier III variants, companion diagnostic clinical evaluation, tissue and plasma registration, and HLA-B*58:01 analytical validation.

July 16, 2026
China CMDE Releases New Review Documents for Oncology NGS & HLA-B*58:01 Reagents
Previous
Previous

Cisema's Hong Kong Office

Cisema (Hong Kong) Limited

7/A, Shun Pont Commercial Building
5–11 Thomson Road, Wan Chai
Hong Kong

Contact Us

Get in Touch with Our Life Sciences Team

And discover how we can support you in achieving approval in the voluntary system for your in vitro diagnostic in Hong Kong.

Request Proposal